MedTrace Logo

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

NCT07358806 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-01-22

No results posted yet for this study

Summary

This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety and tolerability as monotherapy and in combination with standard-of-care treatments in patients with advanced solid tumors.

Conditions

Interventions

DRUG

OCT-598

OCT-598 will be administered orally once daily.

COMBINATION_PRODUCT

Docetaxel

Docetaxel will be provided for Part B only to support the combination therapy with the standard-of-care regimen.

Sponsors & Collaborators

  • Oscotec Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-18
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07358806 on ClinicalTrials.gov